CU01 – Kindey Disease
MOA of CU01 : Nrf2 activation & inhibition of TGF- β/Smad signaling
Dual Mechanism of Action:
NRF2 activation + TGF-β inhibition, targeting
oxidative stress and fibrosis
simultaneously.
Efficacy and safety were demonstrated in the Phase 2b clinical trial.
Ph2b results of CU01
Completed the Phase 2b for Diabetic Nephropathy.
Phase 2 demonstrated reduction in UACR, maintained eGFR, and confirmed safety
High Unmet Need
Offers a potential new option in DN and CKD, where current treatments remain limited
Dual Mechanism of Action
NRF2 activation + TGF-β inhibition, targeting oxidative stress,
inflammation, and fibrosis simultaneously.